
Warning letters, 483s, Recalls, Import Alerts, Audit observations
FDA has updated MAPP for assessment of requests for reclassification of facility-based major complete response (CR) letter amendments. On December 21, FDA published a revised CDER manual of policies and procedures (MAPP) to assess requests for reclassification of facility-based major complete response (CR) letter amendments for ANDAs and Prior Approval Supplements (PAS). The MAPP is updated to include information on how to assess the impact of a facility withdrawal on the reclassification request.
Drugmakers can request the reclassification of a facility-based “major” CR letter amendment to a “minor” amendment, without being reinspected if they meet certain conditions. One major concern of the generic industry is the lengthy delays for a reinspection after getting an official action indicted (OAI) on a former inspection. The MAPP elaborates the procedures for OPQ and OGD to more easily resolve these issues.
FDA will review a request for reclassification from major to minor if the following conditions are met:
FDA will deny a request for reclassification request from major to minor if:
Leave a Comment
You must be logged in to post a comment.